Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's programOct 29Quarterly updateAlnylam Pharmaceuticalsnucresiran
Regeneron registers Phase 3 cat allergy trial and Phase 1/2 glaucoma antibody studyJun 30Weekly roundup, 2 itemsfreneslerbartmevonlerbart